0000950170-24-069608.txt : 20240605 0000950170-24-069608.hdr.sgml : 20240605 20240605211540 ACCESSION NUMBER: 0000950170-24-069608 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 241023679 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2024-06-03 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false See Remarks true Common Stock 2024-06-03 4 M false 5000 11.35 A 12314 D Common Stock 2024-06-03 4 S false 5000 30.1832 D 7314 D Common Stock 2024-06-03 4 F false 488 30.17 D 6826 D Common Stock 2024-06-03 4 A false 1232 31.30 A 8058 D Common Stock 2024-06-03 4 A false 1232 0.00 A 9290 D Stock option (right to buy) 11.35 2024-06-03 4 M false 5000 0.00 D 2029-02-08 Common Stock 5000 14167 D Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.17 to $30.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on May 31, 2024 was used to calculate the withholding obligation. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Fully exercisable. Chief Accounting & Technology Officer /s/ Joseph Douglas Lyon 2024-06-05